Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Iron-sulfur Cluster Deficiency, Pulmonary Hypertension, Friedreich Ataxia
Interventions: Right Heart Catheterization, Blood draw; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Myelodysplastic Syndrome, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more

Conditions: Hyperphosphatemia, Anemia, Iron Deficiency, Renal Insufficiency
Interventions: Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Anchorage, Alaska • Mesa, Arizona • Pine Bluff, Arkansas + 6 more

Conditions: Papillary Carcinoma of Thyroid Gland, Metastatic Medullary Thyroid Cancer, Follicular Thyroid Cancer Lymph Node Metastasis
Interventions: Ferumoxytol, Nanoparticle MRI; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
Interventions: Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%; Drug · Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 24 Weeks to 27 Weeks
Enrollment: 1,316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more

Conditions: Pancreatic Cancer
Interventions: Superparamagnetic Iron Oxide Magnetic Resonance Imaging; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcopenia
Interventions: Rapamycin, Amino acid supplementation, Low-intensity resistance exercise, Sodium nitroprusside, Blood flow restriction cuff; Drug · Other · Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Stroke
Interventions: MRI scans with non heme iron levels; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Iron Deficiency
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Rochester, New York

Conditions: POTS - Postural Orthostatic Tachycardia Syndrome
Interventions: Intravenous iron; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anemia
Interventions: ferumoxytol or oral iron; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 19
States / cities: Encino, California • Riverside, California • Tarzana, California + 15 more

Conditions: Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the Brain
Interventions: Ferumoxytol, Gadolinium, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 10 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anemia, Mortality
Interventions: Early anemia diagnosis and treatment, No change from normal routine; Other
Lead sponsor: Fresenius Medical Care North America; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 42
States / cities: Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more

Conditions: HIV Dementia
Interventions: Ferumoxytol; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 19 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Sickle Cell Disease
Interventions: Liver transient elastography (Fibroscan), Ferriscan, Liver biopsy in iron overloaded subjects.; Other · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 10 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Parkinsons Disease (PD)
Interventions: Gamma- glutamylcysteine; Drug
Lead sponsor: Pravat Mandal; Other
Eligibility: 50 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: MRI Scans
Interventions: Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI); Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 2 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: New York, New York

Conditions: Iron Overload, Hemochromatosis, Hemosiderosis
Interventions: MRI; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 8 Years to 89 Years
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Palo Alto, California • Baltimore, Maryland • Dallas, Texas + 1 more

Conditions: Custodial Grandparents
Interventions: Behavioral Parent Training, Cognitive Behavioral Therapy, Psychosocial-Informational support; Behavioral
Lead sponsor: Kent State University; Other
Eligibility: Not listed
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: San Bernardino, California • Baltimore, Maryland • Kent, Ohio + 1 more

Conditions: Receptor Blockade
Interventions: Adenosine Triphosphate, Acetylcholine, Sodium Nitroprusside, Adenosine Diphosphate, Adenosine Monophosphate, Uridine Triphosphate, Adenosine, Vitamin B 6, Pyridoxal 5'-Phosphate; Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Fetal Growth Retardation
Interventions: Ferumoxytol infusion, MRI scan; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Iron Absorption
Interventions: Exercise test; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions: BQ-788, BQ-123, L-Arginine, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Lactated Ringer's; Drug
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular
Interventions: Ferric carboxymaltose IV, Normal Saline (Placebo); Drug
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

Surfactant Positive Airway Pressure and Pulse Oximetry Trial

Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)

Nutritional and Contractile Regulation of Muscle Growth

Non-Heme Iron Load Quantification in the Brain - MRI of Patients With Stroke

Absorption of Heme and Non-Heme Iron in Pregnant and Non-pregnant Women and Mechanisms of Fetal Iron Transfer

Restoring Iron Deficiency in POTS

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

Liver Fibrosis in Sickle Cell Disease

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content

Comparing Interventions To Improve The Well-Being Of Custodial Grandfamilies

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Placental Lesions in Fetal Growth Restrictions

The Effects of Acute Erythropoietin on Hepcidin and Dietary Iron Absorption Following Military-relevant Exercise in Energy Deficit: Pilot Study

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study